IGF2BP3 and cancer: Similarly, the upregulation of the m6A reader IGF2BP3 has been identified as a new biomarker of many cancers; for instance, the co-expression of IGF2BP3 and the lncRNA DDRMR is a diagnostic and prognostic marker in clear cell renal cell carcinoma (ccRCC) (Gu et al., 2021a).